The Trump administration ends a Medicare drug plan subsidy earlier than planned, according to reporting in multiple outlets. The subsidy is tied to Medicare Part D, the prescription drug coverage program for people with Medicare. Coverage of the decision says the subsidy’s end date is moved up and will take effect about a year ahead of the schedule previously announced. Sources characterize the change as an effort to discontinue a specific payment support tied to Medicare drug plans rather than a broader rewrite of Medicare eligibility rules. Details on how beneficiaries or plan costs will be affected are not fully consistent across the brief summaries available, but both reports align on the core point: the administration is terminating the subsidy in advance of the original timeline. No common figures about the subsidy amount, affected regions, or estimated impact on premiums or out-of-pocket costs are included in the provided text. The decision is presented as an administrative policy change affecting Medicare drug coverage financing, with the primary shared emphasis on the earlier-than-expected termination date.